Here is another experimental Phase 1 clinical trial that I find scientifically interesting - so I am keeping a close eye on - another second strategy to attempt to make MSS-CRC "cold" tumors "hot". This one is exclusively for MSS patients & exclusively at Johns Hopkins.
It uses two "epigenetic" drugs in combination with a PD-1 inhibitor. In CRC animal models the drugs remove immunosuppressive signals - so enhance the power of immunotherapies such as PD-1 inhibitors. At least in animal models...
There is no CRC human clinical trial data released yet. https://clinicaltrials.gov/ct2/show/NCT ... 172&rank=1
Preclinical paper it is based on: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4136565/
6/4/2012 Dx Stage 3C CRC @ 40 yo. MSS, KRAS-WT, BRAF-WT, p53-mut
8/13 Enlarged lymphs - Stable
10/14 Stage IV. Lung & Lymph mets. 5-FU+bev
11/15 FOLFIRI + bev
11/16 Signs of FOLFIRI resistance (Lymph mets)
1/17 Palliative radiation for resistant mets
2/17 FOLFIRI + bev + Maraviroc (off-label)
3/17 FOLFIRI + Erbitux + Maraviroc (off-label)MSS-CRC Clinical Trial Finder: http://trialfinder.fightcrc.org/2016 Colondar 2.0 ModelDK37 Science Posts List